AEON BIOPHARMA INC (AEON)

AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024

IRVINE, Calif., Aug. 19, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company...

AEON Stock Earnings: AEON Biopharma Beats EPS for Q2 2024

AEON stock results show that AEON Biopharma beat analyst estimates for earnings per share the second quarter of 2024.

AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

– Progressing plans to develop ABP-450 (prabotulinumtoxinA) injection as a biosimilar utilizing BOTOX® (onabotulinumtoxinA) as the reference product – –...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

It's time to dive into the biggest pre-market stock movers as we check out all of the latest news worth reading about on Tuesday morning!

AEON Stock Earnings: AEON Biopharma Misses EPS for Q1 2024

AEON stock results show that AEON Biopharma missed analyst estimates for earnings per share the first quarter of 2024.

AEON Biopharma Reports First Quarter 2024 Financial Results

– Ongoing analysis of interim data from the Phase 2 study of ABP-450 in chronic migraine, which did not achieve its primary or secondary endpoints – –...

AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine

– Trial did not meet primary endpoint –...

Oversold Conditions For Aeon Biopharma (AEON)

AEON Stock Earnings: AEON Biopharma Reported Results for Q4 2023

AEON Biopharma just reported results for the fourth quarter of 2023.

CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants

IRVINE, Calif., March 30, 2024 (GLOBE NEWSWIRE) -- Regarding a release issued under the same headline on March 29, 2024 by AEON Biopharma, Inc. (NYSE:...

AEON Biopharma Announces Redemption of Public Warrants

IRVINE, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON; AEON.WS) (“AEON” or “the Company”), a clinical-stage...

AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results

– Recent end-of-Phase 2 meeting with FDA resulted in alignment on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive...

AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine

– FDA and AEON align on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine...

AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements

-- Termination of the Forward Purchase Agreements simplifies AEON’s capitalization structure -- -- AEON to expand its Board of Directors with appointment...

AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference

– Open label extension (OLE) Phase 2 data show peak efficacy for all ABP-450 doses and cycles in treating cervical dystonia (CD) occurred early, within 4...

AEON Biopharma Reports Third Quarter 2023 Financial Results

– Announced topline results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the preventive treatment of episodic migraine that support advancing the...